share_log

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $42 Price Target

Benzinga ·  May 17 08:50

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $42 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment